Dicyclomine is an anticholinergic indicated for the treatment of patients with functional bowel/irritable bowel syndrome. It is available as tablets, capsules and injection for oral and intramuscular use. MedsAcross supplies Dicyclomine for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
Dicyclomine hydrochloride tablets are indicated for the treatment of patients with functional bowel/irritable bowel syndrome. Dicyclomine hydrochloride is an antispasmodic and anticholinergic (antimuscarinic) agent indicated for the treatment of functional bowel/irritable bowel syndrome
Source: US FDA prescribing information
Dicyclomine relieves smooth muscle spasm of the gastrointestinal tract. Animal studies indicate that this action is achieved via a dual mechanism: a specific anticholinergic effect (antimuscarinic) at the acetylcholine-receptor sites with approximately 1/8 the milligram potency of atropine ( in vitro, guinea pig ileum), and a direct effect upon smooth muscle (musculotropic) as evidenced by dicyclomine’s antagonism of bradykinin- and histamine-induced spasms of the isolated guinea pig ileum. Atropine did not affect responses to these two agonists. In vivo studies in cats and dogs showed dicyclomine to be equally potent against acetylcholine (ACh)- or barium chloride (BaCl2)-induced intestinal spasm while atropine was at least 200 times more potent against effects of ACh than BaCl2.
Source: US FDA prescribing information
Dosage must be adjusted to individual patient needs. Dosage for dicyclomine hydrochloride tablets must be adjusted to individual patient needs. If a dose is missed, patients should continue the normal dosing schedule. Oral in adults: Starting dose: 20 mg four times a day. After a week treatment with the starting dose, the dose may be escalated to 40 mg four times a day, unless side effects limit dosage escalation Discontinue dicyclomine hydrochloride tablets if efficacy not achieved or side effects require doses less than 80 mg per day after two weeks of treatment
Source: US FDA prescribing information
Dicyclomine hydrochloride is contraindicated in infants less than 6 months of age, nursing mothers, and in patients with: unstable cardiovascular status in acute hemorrhage myasthenia gravis glaucoma obstructive uropathy obstructive disease of the gastrointestinal tract severe ulcerative colitis reflux esophagitis Infants less than 6 months of age. Glaucoma. Nursing mothers. Obstructive uropathy. Unstable cardiovascular status in the acute hemorrhage. Obstructive disease of gastrointestinal tract. Myasthenia gravis. Severe ulcerative colitis. Reflux esophagitis
Source: US FDA prescribing information
Cardiovascular conditions: worsening of conditions. Peripheral and central nervous system: heat prostration can occur with drug use (fever and heat stroke due to decreased sweating), drug should be discontinued and supportive measures instituted. Psychosis and delirium have been reported in patients sensitive to anticholinergic drugs (such as elderly patients and/or in patients with mental illness): signs and symptoms resolve within 12 to 24 hours after discontinuation of dicyclomine hydrochloride tablets. Myasthenia Gravis: overdose may lead to muscular weakness and paralysis. Dicyclomine hydrochloride tablets should be given to patients with myasthenia gravis only to reduce adverse muscarinic effects of an anticholinesterase. Incomplete intestinal obstruction: diarrhea may be an early symptom especially in patients with ileostomy or colostomy.
Source: US FDA prescribing information
The pattern of adverse effects seen with dicylomine is mostly related to its pharmacological actions at muscarinic receptors. They are a consequence of the inhibitory effect on muscarinic receptors within the autonomic nervous system. These effects are dose-related and are usually reversible when treatment is discontinued. The most serious adverse reactions reported with dicyclomine hydrochloride include cardiovascular and central nervous system symptoms. The most serious adverse reactions include cardiovascular and central nervous system symptoms. The most common adverse reactions (> 5% of patients) are dizziness, dry mouth, vision blurred, nausea, somnolence, asthenia and nervousness
Source: US FDA prescribing information
Antiglaucoma agents: anticholinergics antagonize antiglaucoma agents and may increase intraoccular pressure. Anticholinergic agents: may affect the gastrointestinal absorption of various drugs, may also increase certain actions or side effects of other anticholinergic drugs. Antacids: interfere with the absorption of anticholinergic agents
Source: US FDA prescribing information
Store at 20° to 25°C (68° to 77°F), excursions permitted between 15° to 30°C (59° to 86°F). Protect from light.
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
5 presentations of Dicyclomine, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Dicyclomine 20 mg tabletOralGeneric name | — | US FDA | Available on request |
| Dicyclomine 10 mg capsuleOralGeneric name | — | US FDA | Available on request |
| Dicyclomine 20 mg/2 mL injectionIntramuscularGeneric name | — | US FDA | Available on request |
| Dicyclomine 10 mg/5 mL oral solutionOralGeneric name | — | US FDA | Available on request |
| Dicyclomine 40 mg tabletOralGeneric name | — | US FDA | Available on request |
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
| Register | Status | Source |
|---|---|---|
| US FDA | First approved 11 May 1950 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Conditions linked to Dicyclomine in public data. This is not a list of approved uses, see the clinical information.
Yes, on request. MedsAcross lists 5 presentations of Dicyclomine and sources them for licensed hospitals, importers and physicians against valid import documents.
Yes. The US FDA first approved Dicyclomine on 11 May 1950, according to Drugs@FDA.
No listed presentation of Dicyclomine is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Dicyclomine is classified under ATC code A03AA07 (Dicyclomine).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.